Bayer study to reduce treatment burden for patients with macular degeneration

Pharma News: Bayer revealed results from its recently published study in patients with wet age-related macular degeneration (AMD), which evaluated the efficacy and safety of Eylea (aflibercept) with treat-and-extend (T&E) dosing regimens.

The goal of proactive flexible treat-and-extend (T&E) regimens is to reduce the treatment burden associated with anti-vascular endothelial growth factor (VEGF) therapy, while maintaining a patient’s visual acuity gains.

In the ALTAIR trial at week 96, 57% and 60% of treatment-naive EYLEA patients maintained vision with 3-monthly or more injection intervals in the 2-week and 4-week extension groups respectively, with more than 40% able to receive four-monthly injections either with 2- or 4-week adjustments. These intervals were achieved without compromising on vision or safety with results consistent with the pivotal VIEW registration trials.

Bayer Australia told Health Industry Hub “Results from the study provide Australian ophthalmologists with greater flexibility in meeting the individual needs of patients.”

In clinical practice a reduction in treatment burden for ophthalmologists and patients would mean fewer medical appointments and a decrease in waiting lists, while maintaining functional outcomes for wet AMD patients.

Wet AMD is a chronic, degenerative eye disease affecting approximately 133,000 Australians.

Enhance corporate branding and boost thought leadership to attract and retain quality employees. How does your company culture measure up in the Pharma industry, based on results from employee feedback? Get the benchmark analysis by contacting us.

Suppliers & Service Providers: Enhance business visibility, differentiate your brand and maximise your reach with a new benchmark in industry media. Health Industry Hub is the only one-stop-hub connecting Australia’s Pharma, MedTech, and Biotech industry professionals. Discover superior performance with our digital media solutions.